Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.48 |
| ▸ | ERN1 | O75460 | 2/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TPMT | P51580 | 2/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4348393 | 0.87 | ERN1 (0.54) | TTRERN1GPR35MEN1KMT2A | |
| SCHEMBL2404465 | 0.86 | ERN1 (0.57) | TTRERN1CASP6MAPTCRHBP | |
| SCHEMBL2407536 | 0.86 | HCAR2 (0.46) | TTRERN1GPR35MEN1KMT2A | |
| SCHEMBL29386074 | 0.86 | ERN1 (0.57) | TTRERN1CASP6MAPTCRHBP | |
| Niclofolan SCHEMBL1498232 | 0.81 | GPR35 (0.57) | TTRGPR35MEN1KMT2AKDM4E | |
| Niclofolan SCHEMBL29385615 | 0.81 | GPR35 (0.57) | TTRGPR35MEN1KMT2AKDM4E | |
| SCHEMBL2405633 | 0.79 | TTR (0.42) | TTRERN1GPR35MEN1KMT2A | |
| SCHEMBL4348195 | 0.78 | CASP6 (0.48) | TTRERN1GPR35MEN1KMT2A | |
| SCHEMBL2403588 | 0.78 | CA1 (0.50) | TTRMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL5110264 | 0.78 | AKR1C4 (0.56) | TTRGPR35MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | claimed |
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2015-04-02 | — | — | US | disclosed |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2013-03-28 | — | — | US | disclosed |
| US-20110212054-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC. | 2011-09-01 | — | — | US | disclosed |
| US-7790704-B2 | Thrombopoietin mimetics | GlaxoSmithKline, LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7674887-B2 | Thrombopoietin mimetics | GLAXOSMITHKLINE LLC (US) | 2010-03-09 | — | — | US | disclosed |
| US-7648971-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1889838-B1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20090176746-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-20090176973-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED | 2009-07-09 | — | — | US | disclosed |
| US-20080090787-A1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED | 2008-04-17 | — | — | US | disclosed |
| US-20080090996-A1 | Hydroxy-1-azobenzene derivatives, for example, 4'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-3'-hydroxybiphenyl-4-carboxylic acid; 3'-Amino-2'-hydroxybiphenyl-3-carboxylic acid; thrombocytopenia treatment | SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED | 2008-04-17 | — | — | US | disclosed |
| US-7335649-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1889838-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2008-02-20 | — | — | EP | disclosed |
| US-7332481-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1864981-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070179192-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED | 2007-08-02 | — | — | US | disclosed |
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-7160870-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | TTR 199/4885ERN1 4239/4885GPR35 2399/4885 |
| US-20070179192-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | TTR 199/4885ERN1 4239/4885GPR35 2399/4885 |
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | TTR 199/4885ERN1 4239/4885GPR35 2399/4885 |
| US-20080090787-A1 | Thrombopoietin mimetics | MPL, THPO, TEK | TTR 199/4885ERN1 4239/4885GPR35 2399/4885 |
| US-20090176746-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | TTR 199/4885ERN1 4239/4885GPR35 2399/4885 |
| US-20110212054-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | TTR 199/4885ERN1 4239/4885GPR35 2399/4885 |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | TTR 199/4885ERN1 4239/4885GPR35 2399/4885 |
| US-20090176973-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | TTR 199/4885ERN1 4239/4885GPR35 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.